PAD Profile : Spironolactone - Heart failure

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Spironolactone - Heart failure

PAD Profile : Spironolactone - Heart failure

Keywords :

potassium sparing diuretics, aldosterone antagonists, hyperkalaemia

Brand Names Include :

Aldactone

Traffic Light Status

Status 1 of 1.

Status :

Green

Important Preferred

Formulations :

Oral suspension
Tablets

Important Information :

Spironolactone is the preferred aldosterone antagonist for all stages of heart failure.

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

Guidelines

The following guidelines are available for this indication.

Guidelines : Heart failure

Other Drugs

Other Indications

Additional Documents

Type

Document

Review Date

Guidelines (Local)

Spironolactone monitoring in combination with Renin-angiotensin - Jul 16

01 July 2019

Committee Recommendations

Date

Committee Name

Narrative

03 May 2017

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

GENERIC Spironolactone has been considered by the PCN and has been assigned a GREEN traffic light status.

NOTE - the branded product, Aldactone, was considered BLACK at the PCN in May 2017.

SAFETY NOTICE: In Feb 2016 the MHRA highlighted the risk of potentially fatal hyperkalaemia when spironolactone is used in combination with a renin-angiotensin drug in heart failure. The MCG approved the content of a guide which clarifies the monitoring requirements for patients on this combination - see guide below

Associated BNF Codes

02. Cardiovascular System

02.02.03. Potassium-sparing diuretics and aldosterone antagonists